Σημαντικά

 

A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…

In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…

After receiving numerous questions from patients regarding the innovative treatment for β-thalassaemia Reblozyl (luspatercept), approved for use in the US, Europe, and Canada, TIF proceeds to organise an interactive, online…

For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK National Health Service (NHS). Crizanlizumab (Adakveo) by Novartis…

In an effort to understand the prevalence of thalassaemic syndromes and the existent blood supply system available within each country of the South-East Asia Region, the WHO Regional Office for…

With the world still battling with the COVID-19 pandemic and the inequities that surfaced as a result, the most vulnerable and marginalized populations are being disproportionately affected due to both…

TIF has participated in the 71st session of the WHO Regional Committee for Europe between 13–15 September 2021, which gathered six hundred high-level delegates, including over 30 Health Ministers from…

The Chinese biotechnology company EdiGene announced yesterday that the first patient was enrolled in the multicentre, Phase I clinical study of its investigational gene editing hematopoietic stem cell therapy ET-01…